The FDA has approved new drug applications (sNDAs) for Pifeltro in combination with other antiretroviral agents and Delstrigo as a complete regimen for adult patients with HIV-1 infection
The status was provided based on clinical results of SB623, including the phase 2 study of modified stem cells in traumatic brain injury (STEMTRA) trial. SB623 is a
GB-102, a pan-Vascular Endothelial Growth Factor (VEGF) inhibitor and potential twice-per-year therapy is targeted to reduce the need for frequent intravitreal injections in retinal diseases, including wet AMD,
The status was provided based on data from the phase II NOBILITY study in adult patients with proliferative lupus nephritis. Gazyva, in combination with standard of care (mycophenolate
Keytruda is Merck’s anti-PD-1 therapy, while Lenvima is the orally available kinase inhibitor discovered by Eisai. Keytruda plus Lenvima has been approved for the treatment of patients with
This study aims to confirm the predicted relative exposure and dose proportionality of PXL065. PXL065, the deuterium-stabilized R-stereoisomer of pioglitazone, targets mitochondrial pyruvate carrier (MPC) inhibition. PXL065 is
The platform, which went live at Bayer earlier this year, brings internal and external clinical data together with Oracle cloud-based technologies into a single data management and warehousing
Alder BioPharmaceuticals is involved in the discovery, development and commercialisation of novel therapeutic antibodies. As per terms of the deal, Lundbeck will begin a tender offer for all
The company received notice today of the FDA approval of the individual IND application from the treating physician, Caroline Hastings, MD, pediatric hematologist/oncologist at the UCSF Benioff Children’s
The data from ASCLEPIOS I and II studies has demonstrated that ofatumumab was superior to Aubagio (teriflunomide) in patients with relapsing forms of MS (RMS). Both trials are
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.